How Hemobag® Saves Money
With the cost of blood products skyrocketing and the costs associated with the morbidity of receiving Donor Blood Products growing, it just makes sense to save as much as possible of the patient's own blood components and reverse hemodilution with the Hemobag®, a quick and easy new form of volume management and ATS, with proven outcomes.
Below are some recent examples of hospital reported data from clinical use of Hemobag® in post-CPB circuit volume processing, as reported and reviewed by a Hospital Value Analysis Committee.
Hospital A
Blood Utilization Hemobag® Group (N=51)
| Number of Units Transfused | |||
|---|---|---|---|
| IntraOp | PostOp | Total | |
| RBC's | 63 | 84 | 147 |
| FFP | 26 | 41 | 67 |
| Platelets | 0 | 20 | 20 |
| Cryo | 69 | 29 | 98 |
Blood Utilization Non-Hemobag® Group (N=47)
| Number of Units Transfused | |||
|---|---|---|---|
| IntraOp | PostOp | Total | |
| RBC's | 86 | 150 | 236 |
| FFP | 76 | 98 | 174 |
| Platelets | 40 | 70 | 110 |
| Cryo | 90 | 64 | 154 |
Click to see the details of
savings per procedure
Hospital B
First 40 Procedures Evaluation
| Blood Component | Percentage Reduction |
|---|---|
| RBC's | 64% |
| FFP | 52% |
Platelets (units) |
73% |
| Cyro | 14% |
Percent Reduction in Allogeneic Units from Prior Year Average
First 40 Procedures
First Six Months of Clinical Use (>125)
Reduction in Allogenic Blood Component Direct Costs
First 6 Months
Based on these studies, using the Hemobag®, your Hospital could potentially save
With the cost of blood products skyrocketing and the costs associated with the morbidity of receiving Donor Blood Products growing, it just makes sense to save as much as possible of the patient's own blood components and reverse hemodilution with the Hemobag®, a quick and easy new form of volume management and ATS, with proven outcomes.
Email us to find out more and learn how easy it is to solve this problem. You can start saving your program costs while improving outcomes immediately!
Hemobag®
